Biomarker ID | 601 |
PMID | 21367627 |
Year | 2011 |
Biomarker | vascular endothelial growth factor (VEGF) |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Tissue |
Subjects | Humans |
Regulation | Upregulated in Lymph Node Metastatis |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways Inlude:- S1P/S1P3 pathway,VEGFR1 pathway,Heart development,Actions of nitric oxide in the heart,Fibroblast growth factor 1 |
Experiment | Lymph Node Metastatis Posititve Lymph Node Metastatis Negative |
Type of Biomarker | Prognostic |
Cohort | 148 CaP patients who underwent radical prostatectomy for clinically localized disease and 10 samples of benign prostatic hyperplasia (BPH) were chosen for the study. Lymph Node Metastatis Posititve(n=10) and Lymph Node Metastatis Negative (n=138) |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p<0.001 |
Method Used | Immunohistochemistry |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | VEGFA |